A Novel DNA Aptamer for Dual Targeting of Polymorphonuclear Myeloid-derived Suppressor Cells and Tumor Cells.

Autor:	Liu H; College of Materials Science and Opto-Electronic Technology, University of Chinese Academy of Sciences, Beijing 100049, China.; Department of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA., Mai J; Department of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA., Shen J; Department of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA., Wolfram J; Department of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA.; Department of Transplantation, Mayo Clinic, Jacksonville, FL 32224, USA., Li Z; Department of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA.; Xiangya Hospital of Central South University, Changsha, Hunan 410013, China., Zhang G; Department of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA., Xu R; Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China., Li Y; Department of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA., Mu C; Department of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA., Zu Y; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX 77030, USA., Li X; Institute of Molecular Medicine and the Department of Nanomedicine and Biomedical Engineering, McGovern Medical School, The University of Texas Health Science Center at Houston, TX 77030, USA., Lokesh GL; Institute of Molecular Medicine and the Department of Nanomedicine and Biomedical Engineering, McGovern Medical School, The University of Texas Health Science Center at Houston, TX 77030, USA., Thiviyanathan V; Institute of Molecular Medicine and the Department of Nanomedicine and Biomedical Engineering, McGovern Medical School, The University of Texas Health Science Center at Houston, TX 77030, USA., Volk DE; Institute of Molecular Medicine and the Department of Nanomedicine and Biomedical Engineering, McGovern Medical School, The University of Texas Health Science Center at Houston, TX 77030, USA., Gorenstein DG; Institute of Molecular Medicine and the Department of Nanomedicine and Biomedical Engineering, McGovern Medical School, The University of Texas Health Science Center at Houston, TX 77030, USA., Ferrari M; Department of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA., Hu Z; College of Materials Science and Opto-Electronic Technology, University of Chinese Academy of Sciences, Beijing 100049, China., Shen H; Department of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA.; Department of Cell and Developmental Biology, Weill Cornell Medicine, New York, NY 10065, USA.
Jazyk:	angličtina
Zdroj:	Theranostics [Theranostics] 2018 Jan 01; Vol. 8 (1), pp. 31-44. Date of Electronic Publication: 2018 Jan 01 (Print Publication: 2018).
DOI:	10.7150/thno.21342
Abstrakt:	Aptamers have the potential to be used as targeting ligands for cancer treatment as they form unique spatial structures. Methods: In this study, a DNA aptamer (T1) that accumulates in the tumor microenvironment was identified through in vivo selection and validation in breast cancer models. The use of T1 as a targeting ligand was evaluated by conjugating the aptamer to liposomal doxorubicin. Results: T1 exhibited a high affinity for both tumor cells and polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). Treatment with T1 targeted doxorubicin liposomes triggered apoptosis of breast cancer cells and PMN-MDSCs. Suppression of PMN-MDSCs, which serve an immunosuppressive function, leads to increased intratumoral infiltration of cytotoxic T cells. Conclusion: The cytotoxic and immunomodulatory effects of T1-liposomes resulted in superior therapeutic efficacy compared to treatment with untargeted liposomes, highlighting the promise of T1 as a targeting ligand in cancer therapy. Competing Interests: Competing Interests: The authors have declared that no competing interest exists.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu